Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotechSOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Ho ...

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

We came across a bullish thesis on Maze Therapeutics, Inc. on deep market scan subreddit by retroviber. In this article, we will summarize the bulls’ thesis on MAZE. Maze Therapeutics, Inc.'s share was trading at $23.25 as of September 15th. MAZE’s forward P/E was 8.53 according to Yahoo Finance. Tempus AI (TEM) Initiated at ‘Buy’ with $60 Price Target by BTIG Sergey Nivens/Shutterstock.com Maze Therapeutics (NASDAQ: MAZE) is showing a compelling move in the small-cap biotech space, driven by a rare com ...

Group 1: Biotechnology Investment Overview - Investing in biotechnology stocks is complex due to the underlying science and high volatility, with double-digit price movements common [1] - Biotech stocks present a compelling risk-reward proposition for long-term investors willing to endure clinical trial phases [1] Group 2: Viking Therapeutics (VKTX) - Viking Therapeutics stock surged in 2024 due to the popularity of GLP-1 weight loss drugs but dropped over 40% in 2025, including a 20% decline after an August clinical trial update [3][4] - The clinical trial showed an average weight loss of 12.2% among patients, but concerns arose over a high dropout rate of 28% and the highest dosage results compared to competitors [4] - Analysts have set a consensus price target of $87.50 for VKTX, indicating a potential upside of 270% from current levels [4] Group 3: ImmunityBio (IBRX) - ImmunityBio stock increased by approximately 8.4% in 2025, primarily due to positive pilot study results for glioblastoma, where all five patients achieved 100% disease control [9][10] - ANKTIVA, the company's drug, received FDA approval for bladder cancer and is being tested for other cancers, HIV, and Long COVID, making it a promising immunotherapy candidate [10] - Analysts have a consensus price target of $10.75 for IBRX, suggesting a potential gain of over 280, but caution is advised as the stock is trading above its 200-day SMA with an RSI of 76 [11] Group 4: Maze Therapeutics (MAZE) - Maze Therapeutics stock has risen approximately 86% since its public trading began in February 2025, with analysts optimistic about further growth [14] - The company reported positive Phase 1 results for its lead candidate MZE782, which targets phenylketonuria (PKU) and chronic kidney disease (CKD), allowing progression to Phase 2 trials [15] - Analysts project a price target of $32.67 for MAZE, with the most bullish estimate at $50, indicating potential for significant growth [16]

PresentationAmy Bachrodt Good morning, everyone, and thank you for joining us today for Maze's event on data from the Phase I clinical trial of MZE782, an oral SLC6A19 inhibitor with potential to treat phenylketonuria or PKU in chronic kidney disease or CKD. [Operator Instructions]. As a reminder, this conference call is being recorded. Before we start, I would like to remind you that today's event, which is intended for the investment community, will include forward-looking statements based on current expe ...

Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.MZE782 has the potential to be a best-in-class therapy for patients with phenylketonuria (PKU), an inherited metabolic disorder, and a first-in-class therapy for chronic kidney disease (CKD).MAZE is reaching significant price levels. See the full breakdown here.Pharmacokinetics (PK)MZE782 demonstrated a favorable plasma PK profi ...

Summary of Maze Therapeutics Conference Call Company Overview - **Company**: Maze Therapeutics (NasdaqGM: MAZE) - **Focus**: Development of precision medicines for kidney and metabolic diseases, leveraging human genetics Key Points from the Call Clinical Development Updates - **MZE-782**: Phase I study completed in healthy volunteers, with Phase II trials expected to start in 2026 for both PKU (Phenylketonuria) and CKD (Chronic Kidney Disease) [2][21] - **MZE-829**: Ongoing Phase II trial for APOL1-mediated kidney disease, with initial top-line data expected in Q1 2026 [2] - **Licensing Agreement**: MZE-001 for Pompe disease licensed to Shionogi & Co. in May 2024 for $150 million upfront, with potential milestone payments and royalties [3] Clinical Data Highlights - **Safety Profile**: MZE-782 demonstrated an excellent safety profile with no serious adverse events reported [10][21] - **Pharmacokinetics (PK)**: Linear and consistent exposure observed across single and multiple ascending dose cohorts, with a half-life of approximately 11 hours [12][20] - **Pharmacodynamics (PD)**: Significant increases in urinary phenylalanine (up to 42-fold) and glutamine (up to 68-fold) excretion observed, indicating effective target engagement [9][15][20] Mechanism of Action - **SLC6A19 Inhibition**: MZE-782 inhibits SLC6A19, a transporter involved in amino acid absorption, which is validated by human genetics and previous clinical data [4][16] - **Kidney Function**: Initial eGFR dip observed, consistent with hemodynamic effects seen with SGLT2 inhibitors, suggesting potential long-term kidney benefits [19][23] Future Plans - **Phase II Trials**: - **PKU**: Focus on plasma phenylalanine reduction as the primary endpoint [22] - **CKD**: Targeting proteinuria reduction as the primary endpoint [22] - **Regulatory Engagement**: Plans to finalize trial designs and seek regulatory input before initiating Phase II studies [22][23] Market Opportunity - **PKU**: Over 60% of patients remain inadequately controlled despite newborn screening, indicating a significant unmet need [5] - **CKD**: Targeting patients who do not adequately respond to current therapies, including SGLT2 inhibitors [6][22] Additional Insights - **Combination Therapy Potential**: Exploration of MZE-782 in combination with existing therapies for enhanced efficacy in PKU patients [80] - **Patient Stratification**: Consideration of demographic needs and dosing flexibility in future development efforts [53] Conclusion Maze Therapeutics is positioned to advance MZE-782 into Phase II trials for both PKU and CKD, with promising early clinical data supporting its safety and efficacy. The company aims to address significant unmet needs in these patient populations, leveraging its genetic insights and innovative drug development approach [87][88]

BREAKING: Core CPI Steady, Jobless Claims Highest Since Oct. 2021Shares of Maze Therapeutics (MAZE) catapulted Thursday after its experimental treatment for a rare, genetic disease blew past the company's own expectations.Leerink Partners analyst Joseph Schwartz said Maze could have a best-in-class treatment for phenylketonuria, or PKU. In this condition, the body can't break down phenylalanine, an essential amino acid. The buildup of phenylalanine can lead to intellectual disability, seizures, small head s ...

MZE782 Phase 1 Trial Results - MZE782 demonstrated an excellent safety profile with no serious adverse events observed[18] - MZE782 exhibited linear pharmacokinetics (PK) across single doses ranging from 30 mg to 960 mg, with a half-life of approximately 11 hours[18, 32] - The trial showed up to a 42-fold increase in urinary phenylalanine (Phe) excretion and a 68-fold increase in urinary glutamine (Gln) excretion at Day 7[18] - MZE782 induced a dose-dependent initial estimated glomerular filtration rate (eGFR) dip, similar to SGLT2 inhibitors[18] Planned Phase 2 Trials in 2026 - The company plans to initiate Phase 2 trials for both Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) in 2026[18] - The PKU Phase 2 trial aims to demonstrate proof-of-concept (PoC) with plasma Phe reduction as the endpoint[56] - The CKD Phase 2 trial will focus on demonstrating PoC with proteinuria reduction as the primary endpoint[56] MZE782 Therapeutic Potential - MZE782 aims to deliver potential best-in-class plasma phenylalanine (Phe) reduction with a good safety profile for PKU patients[17] - MZE782 could be a new mechanism of action (MoA) to address CKD patients with inadequate response to current therapies, including SGLT2 inhibitors[56] Company Financial Position - The company has a strong cash position with an expected runway into 2028[12]

Core Viewpoint - Maze Therapeutics has successfully entered into an oversubscribed private placement agreement, raising approximately $150 million to advance its clinical programs and research initiatives [1][4]. Group 1: Private Placement Details - The private placement consists of 4,000,002 shares of common stock priced at $16.25 per share, along with 5,231,090 pre-funded warrants priced at $16.249 each [3]. - The transaction is expected to close on September 12, 2025, pending customary closing conditions [4]. - The placement has attracted both new and existing investors, including notable firms such as Frazier Life Sciences and Janus Henderson Investors [2]. Group 2: Use of Proceeds - Proceeds from the private placement will be utilized to further the development of MZE829 for APOL1-mediated kidney disease, initiate Phase 2 trials for MZE782 targeting phenylketonuria and chronic kidney disease, and support ongoing research and development efforts [4]. - Additional funds will be allocated for working capital and general corporate purposes [4]. Group 3: Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [8]. - The company's lead candidates include MZE829, an APOL1 inhibitor in Phase 2 development, and MZE782, a SLC6A19 inhibitor also advancing to Phase 2 [8].